一次情報の記録
重要申請提出
Inhibrx、従来型軟骨肉腫を対象にozekibartのBLAを提出
Inhibrxは2026年4月に従来型軟骨肉腫を対象にozekibartのBLAをFDAに提出した。同社はまた、2026年後半にFDAとCRCにおける一次治療の登録試験およびCRC四次治療および難治性Ewing肉腫におけるozekibartの加速承認経路について協議する予定である。
主要事実
出典の抜粋
EX-99.1 2 exhibit99103312026.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports First Quarter 2026 Financial Results San Diego, CA, May 14, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming Milestones • INBRX-106 ◦ In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (Combin